Day One Biopharmaceuticals Reports Strong OJEMDA Sales, Details Mersana Acquisition, and Strategic Partnerships in Annual Filing
Summary
Day One Biopharmaceuticals' 2025 annual report showcases strong OJEMDA product revenue, the strategic acquisition of Mersana Therapeutics to expand its oncology pipeline, and a significant international partnership for tovorafenib, despite continued net losses.
Key Events
-
Strong OJEMDA Product Revenue Growth
Net product revenue from OJEMDA increased significantly to $155.4 million in 2025, up from $57.2 million in 2024, driven by its successful commercial launch in the United States.
-
Strategic Mersana Therapeutics Acquisition
The acquisition of Mersana Therapeutics, Inc. closed on January 6, 2026, for approximately $128.8 million in cash plus contingent value rights (CVRs), adding Emiltatug Ledadotin (Emi-Le), a B7-H4-targeted ADC for adenoid cystic carcinoma, to the oncology pipeline.
-
Ipsen Partnership for Ex-US Commercialization
The company licensed exclusive ex-US commercialization rights for tovorafenib to Ipsen Pharma SAS in July 2024, receiving a $70.8 million upfront fee and a $40.0 million equity investment, with potential for up to $375.0 million in additional milestones and tiered double-digit royalties. The EMA submission for tovorafenib was validated in March 2025.
-
Pipeline Advancement for DAY301
DAY301, a PTK7-targeted Antibody Drug Conjugate (ADC), advanced into Phase 1a/b clinical trials, with initial clinical data expected in the second half of 2026.
Analysis
Day One Biopharmaceuticals' annual report highlights significant commercial progress with its lead product, OJEMDA, demonstrating substantial revenue growth in 2025. The company also detailed the strategic acquisition of Mersana Therapeutics, which closed in January 2026, expanding its oncology pipeline with the addition of Emiltatug Ledadotin (Emi-Le). Furthermore, the filing provides comprehensive information on the Ipsen partnership for ex-US commercialization of tovorafenib, including significant upfront payments and future milestone potential. While the company continues to incur net losses, these strategic moves and commercial successes are crucial for its long-term growth and market position in the life sciences sector.
At the time of this filing, DAWN was trading at $12.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.64 to $13.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.